Background: Limited success of previous clinical trials for Fragile X syndrome (FXS) has led researchers to consider combining different drugs to correct the pleiotropic consequences caused by the absence of the Fragile X mental retardation protein (FMRP). Here. we report the results of the LovaMiX clinical trial. the first trial for FXS combining two disease-modifying drugs. https://www.hindirochakkahaniya.com/